New Two-Drug attack on advanced cancers begins human testing

NCT ID NCT07392736

Summary

This early-stage trial is testing a new oral drug, AL8326, combined with an existing immunotherapy (toripalimab) for people with advanced solid tumors that have come back or spread. The main goals are to find the safest and most effective dose of the new combination and to see if it can shrink tumors. The study will enroll about 228 adults whose cancer has progressed despite standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital of Shantou University Medical College

    RECRUITING

    Shantou, Guangdong, 515000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Guangxi Medical University Cancer Hospital

    RECRUITING

    Nanning, Guangxi, 530021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hunan Cancer Hospital

    RECRUITING

    Hunan, Changsha, 410000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Liuzhou Workers' Hospital

    RECRUITING

    Liuchow, Guangxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National GCP Center for Anticancer Drugs,The Independent Ethics Committee

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SIR RUN RUN SHAW Hospital Zhejiang University School Of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310016, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Cancer Hospital of the Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Guilin Medical Universty

    RECRUITING

    Guilin, Guangxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi’an, Shanxi, 710000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, 450000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    RECRUITING

    Nanning, Guangxi, 530000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yuebei People's Hospital

    RECRUITING

    Shaoguan, Guangdong, 51200, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.